Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
life sciences
national blog main
new york top stories
7
×
national top stories
new york blog main
san francisco top stories
boston blog main
boston top stories
clinical trials
indiana blog main
indiana top stories
national
san diego blog main
san diego top stories
san francisco blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
novartis
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
biogen
cancer
europe top stories
gene therapy
medicare
merck
pfizer
roche
alnylam pharmaceuticals
What
patients
7
×
drug
fda
bio
medicine
roundup
friday
market
new
therapy
type
acquisitions
advantages
ago
albert
alnylam
approval
approve
approved
atrophy
awaits
bar
becker
bid
biggest
billions
biological
boehringer
bourla
brings
cancer
ceo
company
crispr
crossed
daily
decades
decision
diabetes
discovered
Language
unset
unknown
Current search:
patients
×
biotech
×
" new york top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision